Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort

Abstract

These data argue for the potential clinical utility of JCV serology for PML risk stratification. However, further investigations of fluctuations in serostatus and of antibody levels for a more precise understanding of the predictive value are warranted.